Class Action Filed Against GSK plc (GSK) – April 7, 2025 Deadline to Join

Core Viewpoint - GSK plc is facing a class action lawsuit related to the alleged misleading statements regarding the withdrawal of Zantac from the market and its connection to cancer risks [3][4]. Group 1: Allegations and Background - The class period for the lawsuit is from February 5, 2020, to August 14, 2022 [3]. - The complaint alleges that GSK misrepresented the reasons for removing Zantac, claiming it was based on available information and regulatory correspondence, while being aware of the source of NDMA for nearly 40 years prior to the withdrawal [3]. - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which the lawsuit claims was materially false or misleading [3]. Group 2: Shareholder Actions - Shareholders who purchased GSK shares during the specified class period are encouraged to register for the class action, with a deadline of April 7, 2025, to seek lead plaintiff status [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].